Altogether, these data support the usefulness of the MP cell line and corresponding subcutaneous xenografts for investigating therapeutic strategies targeting p53-defective HCC and/or c-MET-activated HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.